Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases.

ABSTRACT: The management of breast cancer brain metastases (BCBM) has historically involved local therapies. However, as novel systemic treatments have become more effective in controlling visceral disease, BCBM have also been better controlled. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in brain metastases in patients with lung cancer and melanoma and represent a promising option for patients with triple-negative BCBM, a group with limited systemic therapy options. In this review we summarize current data about the role of ICIs in the treatment BCBM. We identified 15 clinical trials that evaluated ICIs ± chemotherapy in patients with breast cancer. The studies were mostly focused on triple-negative breast cancer (TNBC). Of these trials, 4 excluded patients with BCBM, while 11 al

SUBMITTER: Schlam I 

PROVIDER: S-EPMC9256020 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature